Kips Bay Medical Announces the First eSVS Mesh Implant by

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Kips Bay Medical Announces the First eSVS Mesh Implant by the Valley Hospital of New Jersey

MINNEAPOLIS, Nov. 11, 2014 (GLOBE NEWSWIRE) -- Manny Villafaña, Chairman and CEO of Kips Bay Medical, Inc. (OTCQB:KIPS), announced that on November 4, 2014, cardiac surgeons at The Valley Hospital's Heart and Vascular Institute in Ridgewood, New Jersey, performed their first implant of an eSVS ® Mesh. This implant was performed as part of the Kips Bay Medical eMESH I clinical feasibility trial currently being conducted for the U.S. Food and Drug Administration (FDA) in a number of preeminent cardiac surgery centers in both Europe and the United States. 

The procedure was performed by Alex Zapolanski, M.D., Director of Cardiac Surgery at The Valley Hospital and Clinical Professor of Surgery, Columbia University College of Physicians and Surgeons; and Juan B. Grau, M.D., Director of Cardiac Translational Research at The Valley Hospital and Associate Professor of Surgery, Columbia University College of Physicians and Surgeons and site principal investigator; at the Valley Hospital Heart and Vascular Institute. Dr. Zapolanski commented, "After completing my first case, I found the eSVS Mesh to be remarkably easy to implant and feel very comfortable with the device. I am pleased that we are able to be part of the eMESH I trial and it is my hope that this device will open the door to improved long-term outcomes for CABG surgery patients."

The eMESH I clinical feasibility trial is a multi-center, randomized study of external saphenous vein graft (SVG) support using Kips Bay Medical's eSVS Mesh in coronary artery bypass grafting (CABG) surgery. The objective of the trial is to demonstrate to the FDA the initial safety and performance of the eSVS Mesh for use as an external SVG support device during CABG surgery. If the trial is successful, the Company intends to use the data from this study as the basis for the filing of a request for an investigational device exemption, or IDE, to perform a larger pivotal study.

About the eSVS Mesh

The eSVS Mesh is designed to be fitted like a sleeve on the outside of saphenous vein grafts to strengthen SVGs used in coronary artery bypass graft surgery. By strengthening the SVG and preventing the damaging expansion of the vein graft, the Company hopes to reduce or prevent the resulting injury which can lead to SVG failure and potentially costly and complicated re-interventions for patients undergoing CABG surgery. The eSVS Mesh is manufactured from nitinol wire which gives the eSVS Mesh considerable strength, while remaining highly flexible and kink-resistant. Kips Bay is currently conducting a feasibility trial for the FDA, the objective of which is to demonstrate the initial safety and performance of the eSVS Mesh. Kips Bay expects to enroll up to 120 patients at ten European and seven U.S. sites and, if the trial is successful, intends to use the data from this study as the basis for the filing of a request for an IDE to perform a larger pivotal study which is required to demonstrate clinical effectiveness and support a request for approval to sell the eSVS Mesh in the United States. Additional information about the eSVS Mesh and the Company's feasibility trial are available at the Company's website at www.KipsBayMedical.com and in the Company's most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission.

About the Valley Hospital

The Valley Hospital is a fully accredited, acute care, not-for-profit hospital serving more than 440,000 people in 32 towns in Bergen County and adjoining communities. The Valley Hospital is part of Valley Health System that also includes Valley Home Care and Valley Medical Group. The Valley Hospital is affiliated with the New York-Presbyterian Healthcare System. Known throughout northern New Jersey for its medical and technical excellence, Valley is a leader in the field of cardiology services. The service includes a full range of diagnostic and interventional cardiac treatment services, including cardiac surgery, coronary angioplasty and electrophysiology studies. At the forefront of the development of new techniques in open heart surgery, Valley offers Off-Pump Coronary Artery Bypass (OPCAB), one of the newest procedures available today.

For more information about The Valley Hospital, visit www.valleyhealth.com .

About Kips Bay Medical

Kips Bay Medical, Inc. is a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, the eSVS Mesh, for use in coronary artery bypass grafting surgery. Kips Bay originally acquired the eSVS Mesh technology from Medtronic, Inc. in 2007. Additional information about Kips Bay is available at the Company's website at www.KipsBayMedical.com .

Forward-Looking Statements Safe Harbor

Statements contained in this release that relate to future events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations of future events and often can be identified by words such as "believes," "expects," "continues," "intends," "should," "will," "may," "can be," "believes," "could," "hopes," "anticipates," "objective," "future," other words of similar meaning or the use of future dates. Examples of forward-looking statements in this release include Kips Bay's plans and expectations regarding enrollments, patients required to complete its trial and other aspects of its eMESH I clinical feasibility trial and the safety, performance and benefits of the eSVS Mesh. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Kips Bay's actual results to be materially different than those expressed in or implied by Kips Bay's forward-looking statements. For Kips Bay, such uncertainties and risks include, in particular, the status of the eMESH I clinical feasibility trial, including enrollment, completion and the results; and its need for, and ability to obtain, additional financing; and the terms of any such additional financing, which could be highly dilutive and adversely affect the rights of its current stockholders. If Kips Bay is unable to obtain additional financing when needed or if its eMESH I clinical feasibility trial is not successful, the Company may not be able to continue as a going concern and may be forced to cease operations. Other uncertainties and risks that may cause Kips Bay's actual results to be materially different than those expressed in or implied by Kips Bay's forward-looking statements include, among others, Kips Bay's future operating results and financial performance; surgeon acceptance of the eSVS Mesh technology; the ability of Kips Bay and its distributors to commercialize and sell the eSVS Mesh in Europe; its ability to obtain coverage and reimbursement from third-party payors for the eSVS Mesh technology and the extent of such coverage; the development of its distribution and marketing capabilities; and its ability to retain and attract personnel. More detailed information on these and other factors that could affect Kips Bay's actual results are described in Kips Bay's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. Kips Bay undertakes no obligation to update its forward-looking statements.

Contact:

Kips Bay Medical, Inc. 
Manny Villafaña, Chairman and Chief Executive Officer, +1-763-235-3540 
Email: Manny.Villafana@KipsBayMedical.com

or

Scott Kellen, Chief Operating Officer and Chief Financial Officer, +1-763-235-3540 
Email: Scott.Kellen@KipsBayMedical.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lithium's Next Leg Depends on Storage, Not EV Hype

Updated Category News Views 67

Grid batteries are quietly becoming lithium’s second engine, and that matters more than another flashy electric-vehicle sales headline. The market is projected to rise from $40.87 billion in 2026 to $57.77 billion by 2031, a 7.2% compound annual growth rate. Respectable growth, certainly. But this is not a straight line, and anybody treating a five-year market forecast...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 82

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
CATL Makes Its APEC Case Beyond the Electric Car Market

Updated Category News Views 63

A 99-Second Pitch With Bigger Ambitions Battery swapping got a rare moment in the geopolitical sunlight at Shenzhen's APEC CEO Summit, and CATL was plainly trying to make that moment count. Dr. Robin Zeng, the company's founder, chairman and chief executive, used the opening business dialogue to argue that the Asia-Pacific region holds more opportunity than trouble. Fair...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 83

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 94

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
Haemonetics Opens Europe for VASCADE MVP XL Device

Updated Category News Views 87

A larger collagen plug is hardly cocktail-party material, yet it can matter a great deal when it sits inside a procedure workflow hospitals are trying to speed up. Haemonetics has received CE Mark certification under the EU Medical Device Regulation for VASCADE MVP XL, its larger-bore venous vascular closure system, and first commercial European procedures were completed...

Continue Reading
IIT Madras Maps 100 Brains in a Serious Science Bet

Updated Category News Views 40

A human brain turned into a navigable cellular map is not a flashy launch-day trinket. It is painstaking infrastructure, the kind that can sit quietly for years before researchers figure out what it truly unlocks. That is why the Sudha Gopalakrishnan Brain Centre mission at IIT Madras deserves a serious look rather than the usual chest-thumping over a big scientific...

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 30

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
Mar-Jac's Safety Milestone Carries Real Operational Weight

Updated Category News Views 16

Four million worked hours without a lost-time accident is the sort of number that ought to make people pause, especially in poultry processing. Mar-Jac Poultry’s Gainesville facility earned Workplace Safety recognition from the Greater Hall Chamber of Commerce after reaching that mark, and this is one corporate achievement that deserves a little less eye-rolling than...

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 110

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading

Top 5 Most Recently Viewed Articles

ChargePoint Faces Share Decline Following Q2 Financial Report

Updated Category News Views 67

Overview of ChargePoint's Stock Performance ChargePoint Holdings Inc (NYSE: CHPT) has seen a drop in its stock value following the release of disappointing financial results for the second quarter. Investors are carefully examining the details of the report, which highlighted significant challenges the company faced during this time. Q2 Financial Highlights In the second...

Continue Reading
Exciting March Madness Audio Coverage by Westwood One 2025

Updated Category News Views 244

Comprehensive Audio Coverage of NCAA Men's Basketball Tournament As the NCAA Men's Basketball Tournament approaches, fans are gearing up for what promises to be an exciting series of games. This year, Cumulus Media's Westwood One (NASDAQ: CMLS) will provide exclusive multiplatform audio coverage of the entire tournament, ensuring that fans can enjoy every moment, whether...

Continue Reading
Cartesian Therapeutics Advances Myasthenia Gravis Treatment Trials

Updated Category News Views 118

Advancements in Myasthenia Gravis Treatment by Cartesian Therapeutics Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a pioneering company in mRNA cell therapy, is making significant strides in developing groundbreaking treatments for autoimmune diseases, especially myasthenia gravis (MG). With encouraging updates from the Phase 2b trial of their leading candidate,...

Continue Reading
Centrifuge Market Set to Surpass $689 Million Amid Growth

Updated Category News Views 147

Growth of the Centrifuge Market: An In-Depth Analysis The centrifuge market is undergoing a remarkable transformation, with projections indicating an increase from USD 463 million in 2023 to an impressive USD 689.91 million by 2032. This growth is driven by a compound annual growth rate (CAGR) of 4.53% from 2024 to 2032, fueled by advancements in biotechnology,...

Continue Reading
National Bank Holdings Sees Price Target Increase by Piper Sandler

Updated Category News Views 58

Piper Sandler Raises Price Target for National Bank Holdings Piper Sandler has recently reviewed its financial outlook for National Bank Holdings (NYSE: NBHC), making a significant update to its price target. The new target has been set at $48.00, an increase from the previous target of $44.00. Current Stock Rating and Rationale The firm has maintained a Neutral rating on...

Continue Reading